Atezolizumab + Capecitabine + Oxaliplatin + Docetaxel
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Cancer
Conditions
Stomach Cancer, Gastro Esophageal Junction Cancer
Trial Timeline
Mar 7, 2018 → Oct 31, 2026
NCT ID
NCT03448835About Atezolizumab + Capecitabine + Oxaliplatin + Docetaxel
Atezolizumab + Capecitabine + Oxaliplatin + Docetaxel is a phase 2 stage product being developed by Roche for Stomach Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03448835. Target conditions include Stomach Cancer, Gastro Esophageal Junction Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03448835 | Phase 2 | Active |
Competing Products
20 competing products in Stomach Cancer